Literature DB >> 24751818

R&D productivity: on the comeback trail.

Ulrik Schulze1, Mathias Baedeker2, Yen Ting Chen3, David Greber1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24751818     DOI： 10.1038/nrd4320

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Does size matter in R&D productivity? If not, what does?

Authors:  Michael Ringel; Peter Tollman; Greg Hersch; Ulrik Schulze
Journal:  Nat Rev Drug Discov       Date:  2013-10-18       Impact factor: 84.694

2.  Identifying R&D outliers.

Authors:  Peter Tollman; Yves Morieux; Jeanine Kelly Murphy; Ulrik Schulze
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694
  2 in total
  4 in total

1.  This time may be different.

Authors:  Bruce L Booth
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

Review 2.  Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease.

Authors:  Tae-Wan Kim
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

3.  Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial Asthma.

Authors:  Eunji Shin; Yong Chul Lee; So Ri Kim; Soon Ha Kim; Joonghoon Park
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

4.  Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.

Authors:  Fiona Sewell; Kathryn Chapman; Jessica Couch; Maggie Dempster; Shawn Heidel; Lise Loberg; Curtis Maier; Timothy K Maclachlan; Marque Todd; Jan Willem van der Laan
Journal:  MAbs       Date:  2017-05-05       Impact factor: 5.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.